Clinical Trial

68Ga-FAPI PET/CT in Malignant Tumors

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 5, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-27; most recent amendment 2025-05-31.
Trial Details
NCT Number NCT05034146
Lead Sponsor Zhongnan Hospital
Conditions Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
Enrollment 500 participants
Start Date 2021-02-23
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-05